Adial Pharmaceuticals, Inc (ADIL) earnings
ADIL earnings moved a median of -0.11% by the close. Quarterly and annual ADIL reports and results, each read against the price at its own news timestamp. Back to the ADIL overview →
20 measured ADIL earnings events.
Where these ADIL earnings landedvs 20 measured ADIL earnings reactions
| Middle 50% of ADIL earnings reactions | -2.38% to +2.94% |
|---|---|
| Median reaction (to close) | -0.11% |
| Measured reactions | 20 |
Point-in-time · zero look-ahead
Half of the 20 ADIL earnings events with a measured close landed between -2.38% and +2.94%; 50% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q ADIAL PHARMACEUTICALS, For: Jun 30 | SEC filing · Form 10-Q | +3.13% | +29.95% | |
| Form 10-Q ADIAL PHARMACEUTICALS, For: Mar 31 | SEC filing · Form 10-Q | +0.00% | -2.04% | |
| Form 10-K ADIAL PHARMACEUTICALS, For: Dec 31 | SEC filing · Form 10-K | -6.09% | -7.11% | |
| Adial Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | -0.93% | +3.87% | |
| Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | -2.00% | +2.71% | |
| Form 10-Q ADIAL PHARMACEUTICALS, For: Jun 30 | SEC filing · Form 10-Q | -2.00% | +2.71% | |
| Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | -2.58% | -2.22% | |
| Form 10-Q ADIAL PHARMACEUTICALS, For: Mar 31 | SEC filing · Form 10-Q | -2.58% | -2.22% | |
| Form 10-K ADIAL PHARMACEUTICALS, For: Dec 31 | SEC filing · Form 10-K | -6.80% | -5.53% | |
| Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update | Press release | +0.93% | -2.84% | |
| Form 10-Q ADIAL PHARMACEUTICALS, For: Sep 30 | SEC filing · Form 10-Q | +12.67% | +3.64% | |
| Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update | Press release | +1.05% | +1.59% | |
| Form 10-Q ADIAL PHARMACEUTICALS, For: Jun 30 | SEC filing · Form 10-Q | +1.05% | +1.59% | |
| Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update | Press release | +6.54% | +3.65% | |
| Form 10-Q ADIAL PHARMACEUTICALS, For: Mar 31 | SEC filing · Form 10-Q | +6.54% | +3.65% | |
| Form 10-K ADIAL PHARMACEUTICALS, For: Dec 31 | SEC filing · Form 10-K | -0.67% | +2.50% | |
| Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update | Press release | +0.00% | -1.81% | |
| Form 10-Q ADIAL PHARMACEUTICALS, For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -1.81% | |
| Form 10-Q/A ADIAL PHARMACEUTICALS, For: Jun 30 | SEC filing · Form 10-Q | +2.25% | -3.50% | |
| Form NT 10-Q/A ADIAL PHARMACEUTICALS, For: Jun 30 | SEC filing · Form NT | +2.25% | -3.50% |
Keep exploring
More ADIL: analyst actions → · SEC filings → · ADIL overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Vivakor, Inc. (VIVK) | 243 | -0.30% | 36% |
| IKANG HEALTH CARE GROUP (KANG) | 242 | -0.07% | 44% |
| Dare Bioscience, Inc. (DARE) | 241 | 0.00% | 43% |
| Genprex, Inc. (GNPX) | 241 | -1.17% | 33% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.